Navigation Links
FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body
Date:10/14/2011

the level of a liver enzyme that may be indicative of tissue or liver damage at unsafe amounts.

The most serious side effect seen in about two percent of patients treated with Ferriprox was the development of agranulocytosis, a serious and potentially life-threatening reduction in the number of granulocytes (a type of white blood cell that fights infection).

The therapy is being approved under the FDA's accelerated approval program, designed to provide patients with earlier access to promising new drugs followed by further studies to confirm the drug's clinical benefit.

The accelerated approval program allows the agency to approve a drug to treat a serious disease based on clinical data showing that the drug has an effect on an endpoint that is reasonably likely to predict a clinical benefit to patients, or on an effect on a clinical endpoint other than survival or irreversible morbidity (illness).

ApoPharma has agreed to several post-marketing requirement and commitments. One commitment includes further study of the use of Ferriprox in patients with sickle cell disease who have transfusional iron overload.

Earlier this year, the U.S. Department of Health and Human Services (HHS) launched the Sickle Cell Disease (SCD) Initiative bringing together HHS agencies to enhance the quality and quantity of SCD data, develop best practice guidelines and quality of care metrics, improve health care delivery and coordination of care for patients with SCD, facilitate approval of new medical products, and expand research on SCD.  The post-marketing requirement for further study of Ferriprox aligns with the goals of the SCD Initiative.

Ferriprox is marketed by ApoPharma Inc. of Toronto.

For more information:

FDA: Office of Hematology and Oncology Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

FDA: Spotlight o
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 A new report ... (Product type, Form, End user, Application and Geography) - ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", ... Based on key trends tracked, it is anticipated that ... billion by 2020, registering a CAGR of 6.2% from ...
(Date:10/22/2014)...  Early symptoms of diabetic eye and vision ... technology, coupled with yearly, comprehensive eye exams, are ... of eye diseases, including those associated with diabetes, ... untreated, these diseases can potentially lead to vision ... optometric researchers have deployed a new tool that ...
(Date:10/22/2014)... Oct. 22, 2014 Sanomedics International Holdings, Inc. ... by Global Research & Data Services, demand for thermometers ... 2014 through 2018, as demand for more accurate digital ... is the world,s largest market for thermometers, and one ... is Sanomedics International Holdings, Inc. Sanomedics International ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2
(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... 2014 With the Affordable Care Act (ACA) ... the American Institutes for Research (AIR) finds that three out ... health insurance, but 42 percent say they are not likely ... signing up for coverage. , The AIR survey found wide ... able to calculate correctly how much they owe for a ...
(Date:10/22/2014)... Your Body’s Way , In a world where a multi-billion-dollar ... can be difficult to choose the right weight loss method. ... it the healthy way? Set aside the fads and resist ... regularly, and choose foods with the most nutritional benefits. ... exercise more and eat less. Despite the number of advertisements ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... world,s leading publisher of scientific, technical and ... acquisition of the,publishing assets of William Andrew, ... Elsevier and William Andrew have built a ... Andrew books globally,outside of North America and ...
... ) is pleased to announce the launch of our redesigned website ... and other healthcare professionals in the United States have relied on ... information at the point-of-care.The new site will continue to focus on ... features and functionality: , , , ...
... Mass. and CHAPEL HILL, N.C., Jan. 20 ALS ... announced today their collaboration aimed at developing a panel ... therapeutics based on targets identified by ALS TDI that ... disease). The collaboration between the two research centers ...
... Combination Treatment Shows Reduction in Lumpiness and Dimpling , ... ... 2009-- Findings from a new study published in the ... combination treatment using laser energy and fat transplantation shows promise ...
... WESTFORD, Mass., Jan. 20 Cynosure, Inc. (Nasdaq: ... a broad array of light-based aesthetic treatment systems, today ... full-year 2008 conference call on Tuesday, February 10, 2009 ... Executive Officer Michael Davin and Executive Vice President and ...
... advises consumers not to eat anything but jars of ... 20 (HealthDay News) -- Peanut butter products continued to ... and specialty companies joined a growing list of precautionary ... Food and Drug Administration warning over the weekend that ...
Cached Medicine News:Health News:Elsevier Acquires William Andrew Publishing 2Health News:Elsevier Acquires William Andrew Publishing 3Health News:MPR Re-Launches its Up-to-Date Drug Reference Website 2Health News:ALS TDI and Asklepios to Develop New Therapeutic Delivery Options for Treating Lou Gehrig's Disease 2Health News:ALS TDI and Asklepios to Develop New Therapeutic Delivery Options for Treating Lou Gehrig's Disease 3Health News:ALS TDI and Asklepios to Develop New Therapeutic Delivery Options for Treating Lou Gehrig's Disease 4Health News:A Possible Cure for Unsightly Cellulite? 2Health News:A Possible Cure for Unsightly Cellulite? 3Health News:Cynosure to Announce Fourth-quarter and Full-year 2008 Financial Results on February 10 2Health News:More Peanut Butter Products Join Recall List 2Health News:More Peanut Butter Products Join Recall List 3Health News:More Peanut Butter Products Join Recall List 4
... new style of Bright cryostat. Based ... cryostat, the new OTF5000 incorporates the ... and powerful 5040 microtome. A huge ... deals makes the range of OTF5000 ...
... advanced smart processor for paraffin infiltration of ... Proven and enhanced technology with an innovative ... the hallmark of the Leica ASP200. Many ... includes a variety of SMART features to ...
... The electronic, motorized ... for all applications of ... and hard specimens in ... labs. These instruments display ...
... Leica RM2255 rotary microtome, designed for ... and resin-embedded specimens, offers a broad ... research histology laboratory. This microtome meets ... a compact, fully motorized/electronic microtome for ...
Medicine Products: